Collaborations & Alliances

Stelis Biopharma, Oncobiologics Form Bio2Source

The newly formed unit will offer development stage biotech companies access to a suite of CDMO services

Stelis Biopharma and Oncobiologics announced that they will unveil a new contract development and manufacturing (“CDMO”) collaboration at BIO 2018 in Boston.     Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma will offer development stage biotech companies access to a suite of CDMO services. Oncobiologics will utilize its proprietary BioSymphony™ platform to offer mammalian cell process development and bulk drug manufacturing, while Stelis will offer microbial dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters